Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.65 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.65 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.65 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.57 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7540241 | 1.00 | DRD2 (0.65) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| Hydrochloric Acid SCHEMBL30510685 | 1.00 | DRD2 (0.65) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| Hydrochloric Acid SCHEMBL7540838 | 1.00 | DRD2 (0.65) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| SCHEMBL7547852 | 0.98 | DRD2 (0.67) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| SCHEMBL30440801 | 0.98 | DRD2 (0.67) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| SCHEMBL7540827 | 0.98 | DRD2 (0.67) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| Hydrochloric Acid SCHEMBL7541528 | 0.90 | DRD2 (0.55) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| Hydrochloric Acid SCHEMBL7540811 | 0.89 | DRD2 (0.57) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| SCHEMBL7540251 | 0.88 | DRD2 (0.56) | DRD2DRD3DRD4ADRA1AMTNR1A | |
| SCHEMBL7543096 | 0.87 | DRD2 (0.58) | DRD2DRD3DRD4ADRA1AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883599-B1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | claimed |
| CN-1212682-A | Aminotetralin derivatives and composition and method of use thereof | ZENECA LTD (GB) | 1999-03-31 | — | — | CN | claimed |
| EP-0883599-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1998-12-16 | — | — | EP | claimed |
| US-5807897-A | MUSCULAR DISORDERS | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | claimed |
| WO-1997031887-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1997-09-04 | — | — | WO | claimed |
| US-12344570-B2 | Aminotetraline activators of serotonin receptors | ATAI THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240300885-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2024-09-12 | — | — | US | disclosed |
| US-11827580-B2 | Aminotetraline activators of serotonin receptors | ATAI Life Sciences AG (DE) | 2023-11-28 | — | — | US | disclosed |
| WO-2023129909-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2023-07-06 | — | — | WO | disclosed |
| US-20230202965-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-0883599-B1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| CN-1212682-A | Aminotetralin derivatives and composition and method of use thereof | ZENECA LTD (GB) | 1999-03-31 | — | — | CN | disclosed |
| EP-0883599-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1998-12-16 | — | — | EP | disclosed |
| US-5807897-A | MUSCULAR DISORDERS | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | disclosed |
| WO-1997031887-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300885-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR3B, HTR1B, TAAR5 | DRD2 111/4885DRD3 273/4885DRD4 199/4885 |
| US-12344570-B2 | Aminotetraline activators of serotonin receptors | HTR3B, HTR1B, TAAR5 | DRD2 111/4885DRD3 273/4885DRD4 199/4885 |
| US-11827580-B2 | Aminotetraline activators of serotonin receptors | HTR3B, HTR1B, TAAR5 | DRD2 98/4885DRD3 266/4885DRD4 171/4885 |
| US-20230202965-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR3B, HTR1B, TAAR5 | DRD2 111/4885DRD3 273/4885DRD4 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.